Steered by a prestigious Committee, the MedFIT conference programme brings together bright minds to discuss the latest trends in MedTech, diagnostic and digital health, to debate on innovation-driven topics, to foster learning and provoke conversations that matter. International experts will address current industry issues related to collaborationfinancingmarket access and regulation as well as MedTech digitalisation.

All MedFIT’s attendees will have access to a mix of live and on-demand content during the event. This content will be available for 30 days afterwards. They will also have the opportunity to debate with the speakers via interactive online chats.


DAY 1 – Tuesday, December 7th

11:30 am – 12:30 pm CET

How is the changing definition of value in healthcare affecting how MedTech companies operate?

The transition of healthcare systems to value-based care holds critical implications for medical innovation and MedTech companies are being forced to change core aspects of their business and the way products or services are evaluated, purchased, and developed.

Who defines value and in what way? To what extent does this transition affect the way R&D efforts are led and how can incentives be structured to foster innovation? How can the right financial and clinical stakeholders be identified early in development to generate evidence and demonstrate the value of innovative products and services? To what extent does this influence MedTech companies’ collaboration choices? Can it lead to more effective and sustainable business models?


Fostering new collaborations is key to fuel innovation and support R&D needs in MedTech. As global healthcare evolves to deliver more value to patients, partnerships with researchers, hospital leaders, technology experts, payers and innovators are the cornerstone of the medical technologies’ evolution.

DAY 1 – Tuesday, December 7th

1:30 – 2:30 pm CET

Breaking silos: How to incentive interoperability in MedTech and connected health?

Joining the dots of patient data, diagnosis and decision making is the holy grail for connected health. What is standing in the way? Who should drive change? How can further collaboration models lead the way?

DAY 2 – Wednesday, December 8th

2:30 – 3:30 pm CET

How to tackle the growing need for digital health proficiency of medical technology professionals?

The importance of health data is growing rapidly and is now reflected in many issues and applications within the MedTech industry. It brings an abundance of new career paths and functions within the industry but also call for new expertise and training needs. How can further industry-university collaboration participate in bridging the talent gap? What are the best practices to involve healthcare professionals in the early stages of innovative product development and enable data literacy?

DAY 3 – Thursday, December 9th

9:30 – 10:30 am CET

How can start-ups benefit from engaging with corporate early?

What are the benefits or constraints to partner with corporate at the early stages of a start-up? What are MedTech big players looking for in their strategic partnerships and what can they bring to the development of a young company? How to create the win-win scenario to advance technology?

Moderator: Suzanne Elvidge, Freelance writer, Biopharma, Healthcare, Business 


Seed and Series A investments are crucial to transforming new ideas into products and moving start-up teams into small businesses. Finding the right funding sources and equity partners to get from early stage to regulatory approval is far from straightforward. How to identify the initial sources of funding for MedTech R&D projects? What method should you use to fund your project? How to attract venture for early-stage financing?

DAY 1 – Tuesday, December 7th

9:30 – 10:30 am CET

Investors’ perspective on investing in MedTech post COVID-19

Almost two years later, how has COVID-19 pandemic influenced investors and what is the impact on early-stage pattern of investment? Have some sub-sectors started to become more interesting to private equity firms?

DAY 2 – Wednesday, December 8th

11:30 am – 12:30 pm CET

How to address the right investors as boundaries are blurring between traditional Medtech, medical devices and digital health technologies?

How have investment strategies evolved with the digitalisation of the MedTech sector? Are traditional MedTech investors diversifying their portofolios? Are there newcomer investors in the field because of digital heath and new opportunities or investments sources? How do early stage MedTech companies continue to attract investment and on what ground?

4:30 – 5:30 pm CET

From seed stage to regulatory approval: How to get your milestones financed?

Developing a roadmap and trying to understand the timing and cost of all potential steps are keys to avoid falling into funding gaps down the road. This means structuring the necessary funds early to achieve specific milestones and subsequent financing rounds to be achieved. How can a young company finance the large expenses prior to regulatory approval? How to identify the right equity partners and involve them in your ongoing operations?

This panel discussion gathering expert investors and successful entrepreneurs aims to provide a better understanding of the timelines, operations, and budgets required to best measure the available funding options at the onset of new start-ups.

Moderator: Arezki Yaiche, Senior France Correspondent M&A/ Antitrust, Freelance

DAY 3 – Thursday, December 9th

3:00 – 4:00 pm CET

Which alternative funding options to VCs for biotech & MedTech start-ups?
[Common to BioFIT]

There is more money than ever fuelling the biotech and MedTech industries, and different kind of investors are entering the stage with more influence than previously thought possible. What are the expectations and specificities of working with angel investors, disease foundations, private equity firms, cross-over funds and family offices? What are the best funding strategies for biotech & MedTech start-ups?


Planning a market access should start early in the product development process, increasing the chances of successfully bringing an innovation to market. How to keep track on market trends and regulatory requirements while building your strategy? How to build the right business model? This track aims to give a comprehensive approach of the pathway to market for emerging medical technologies.

DAY 1 – Tuesday, December 7th

3:30 – 4:30 pm CET

From big companies to founder: Hear the stories of executives turned MedTech entrepreneurs

DAY 2 – Wednesday, December 8th

9:30 – 10:30 am CET

Case study: Which business model for digital innovations to manage chronic diseases?

Innovative digital solutions intend to make a difference in addressing chronic conditions. As they include and connect a growing number of devices, apps and services to support patients and their caregivers, what are their actual contribution to chronic illness management? What are the current business models for consumers and payers? How are these solutions adopted by the end users and what are their added value?

Moderator: Tobias Silberzahn, Partner, McKinsey & Company

  • Anna King, Commercial Director, Health Innovation Network 
DAY 3 – Thursday, December 9th

11:30 am – 12:30 pm CET

Diagnostic solutions vs. Consumer-grade devices: How is digitalisation blurring the lines?

Evolving consumer expectation and anytime patient data access are making way for non-traditional players to disrupt the healthcare industry. While diagnostic sector has already changed with rising digital medical-grade solutions, what are the challenges additionally brought by the rapid development of consumer-grade devices? How are diagnostic players to stay competitive when an increasing number of consumer-level trackers/apps may successfully turn into certified medical devices? Is the reimbursement model the only one that’s right?